Michael L Cleary
Michael L Cleary
Leukaemia stem cells (LSCs) are responsible for sustaining and propagating malignant disease, and, as such, are promising targets for therapy. Studies of human LSCs have served an important role in defining the major tenets of the cancer st...
Marshall A Lichtman
Marshall A Lichtman
Jane Apperley
Jane Apperley
With the improved survivals offered by the tyrosine kinase inhibitors has come the necessity to address issues relating to quality of life and one such area is that of fertility and parenting. Animal data suggest that imatinib at standard d...
Giovanni Martinelli,Ilaria Iacobucci,Cristina Papayannidis et al.
Giovanni Martinelli et al.
The outcome for adults with Philadelphia chromosome (Ph+) leukaemias (chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL)) has been dramatically improved with the use of tyrosine kinase inhibitors (TKIs), but progression...
Alois Gratwohl,Dominik Heim
Alois Gratwohl
Haematopoietic stem cell transplantation (HSCT) has seen considerable ups and downs in its role for patients with chronic myeloid leukaemia (CML). It has provided the first proof of the principle for cure and has confirmed the concept of su...
Michael J Mauro,Michael W Deininger
Michael J Mauro
Therapy for patients with chronic myeloid leukaemia has grown in complexity, first with the advent of the prototype ABL kinase inhibitor, imatinib, and subsequently with the availability of alternate (currently second-line) inhibitors. Imat...
Advances in the biology and therapy of patients with chronic myeloid leukaemia [0.03%]
慢性粒细胞白血病患者的生物学和治疗进展
Elias Jabbour,Carmen Fava,Hagop Kantarjian
Elias Jabbour
Chronic myelogenous leukaemia (CML) is a progressive and often fatal haematopoietic neoplasm. The Bcr-Abl tyrosine kinase inhibitor imatinib mesylate represented a major therapeutic advance over conventional CML therapy, with more than 90% ...
Richard T Silver
Richard T Silver
The blast phase of chronic myelogeneous leukaemia (BP-CML) still remains a difficult entity to understand pathogenetically and to treat. In recent years, advances have been made in our understanding of the molecular biology and the pathogen...
Pharmacologic monitoring and determinants of intracytoplasmic drug levels [0.03%]
药理学监测及胞浆内药物浓度的影响因素
François-Xavier Mahon
François-Xavier Mahon
Imatinib (IM) is the gold standard for the treatment of chronic myeloid leukaemia (CML). However, there exists significant interpatient variability in plasma exposure for a given dose of the drug. Several recent studies have revealed a corr...